Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jun 14;7(24):37319-37330.
doi: 10.18632/oncotarget.9104.

Establishment and validation of a prognostic nomogram for patients with resectable perihilar cholangiocarcinoma

Affiliations

Establishment and validation of a prognostic nomogram for patients with resectable perihilar cholangiocarcinoma

Peizhan Chen et al. Oncotarget. .

Abstract

As the conventional staging systems have poor prognosis prediction ability for patients with perihilar cholangiocarcinoma (pCCA), we established and validated an effective prognostic nomogram for pCCA patients based on their personal and tumor characteristics. A total of 235 patients who received curative intent resections at the Eastern Hepatobiliary Surgery Hospital from 2000 to 2009 were recruited as the primary training cohort. Age, preoperative CA19-9 levels, portal vein involvement, hepatic artery invasion, lymph node metastases, and surgical treatment outcomes (R0 or R1/2) were independent prognostic factors for pCCA patients in the primary cohort as suggested by the multivariate analyses and these were included in the established nomogram. The calibration curve showed good agreement between overall survival probability of pCCA patients for the nomogram predictions and the actual observations and the concordance index (C-index) was 0.68 (95% CI, 0.61-0.71). The C-index values and time-dependent ROC tests suggested that the nomogram is superior to the conventional staging systems including the Bismuth-Corlette, Gazzaniga, Memorial Sloan Kettering Cancer Center (MSKCC), American Joint Committee on Cancer (AJCC) TNM 7th edition, and Mayo Clinic. The nomogram also performed better than the traditional staging system in the internal cohort with 93 pCCA patients from the same institution and an external validation cohort including 84 pCCA patients from another institution in predicting the overall survival of the pCCA patients as suggested by the C-index values and the time-dependent ROC tests. In summary, the proposed nomogram has superior predictive accuracy of prognosis for resectable pCCA patients.

Keywords: nomogram; overall survival; perihilar cholangiocarcinoma.

PubMed Disclaimer

Conflict of interest statement

The authors have declared no conflicts of interest.

Figures

Figure 1
Figure 1. The survival nomogram for the pCCA patients
(To use the nomogram, the individual patient's value is located on each variable axis, and a line is drawn upward to determine the risk score for each variant. The sum of these scores is located on the total points axis, and a line is drawn downward to the survival axes to determine the probability of 3- or 5-year survival).
Figure 2
Figure 2. Calibration curves for predicting patient survival at
A. 3 years and B. 5 years in the primary cohort and at 3 years in the internal validation cohort C. or external validation cohort D. Nomogram-predicted probability of OS is plotted on the x-axis; actual OS is plotted on the y-axis.
Figure 3
Figure 3. Comparison of the staging systems in the prediction of the OS for pCCA patients in primary training cohort
(A. Bismuth-Corlette; B. Gazzaniga; C. MSKCC; D. AJCC TNM (seventh edition); E. Mayo Clinic; F. Nomogram risk score).

Similar articles

Cited by

References

    1. Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, Rosenberg WM, Tait P, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Wasan H, British Society of G Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 2012;61:1657–1669. - PubMed
    1. Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013;145:1215–1229. - PMC - PubMed
    1. Williams TM, Majithia L, Wang SJ, Thomas CR., Jr Defining the role of adjuvant therapy: cholangiocarcinoma and gall bladder cancer. Semin Radiat Oncol. 2014;24:94–104. - PubMed
    1. Ramirez-Merino N, Aix SP, Cortes-Funes H. Chemotherapy for cholangiocarcinoma: An update. World J Gastrointest Oncol. 2013;5:171–176. - PMC - PubMed
    1. Grendar J, Grendarova P, Sinha R, Dixon E. Neoadjuvant therapy for downstaging of locally advanced hilar cholangiocarcinoma: a systematic review. HPB (Oxford) 2014;16:297–303. - PMC - PubMed

Publication types

MeSH terms

Substances